Search
  • Search


    Human Cot-1 DNA

    HUS-yhtymä

    Human Cot-1 DNA

    1. Competition notice published

      29. jan. kl. 13:0929. januar 2026 kl. 13:09
    2. Questions deadline

      9. feb. kl. 10:009. februar 2026 kl. 10:00
    3. Tender submission deadline

      20. feb. kl. 10:0020. februar 2026 kl. 10:00
    4. Tender validity period

      20. aug. kl. 09:0020. august 2026 kl. 09:00

    Brief

    Finland: Tenders/HUS-yhtymä/Human Cot-1 DNA

    Expired

    The competition has expired without a winner being announced.

    Brief

    Laboratorie- og analyseutstyr

    HUS-yhtymä needs Human Cot-1 DNA, a reagent for array processes during hybridization, to be delivered to the Genetics Laboratory of the HUS Diagnostic Center in Helsinki-Uusimaa. The contract has a fixed duration of 2 years, with an estimated total value of approximately 80 000 EUR over 48 months. The estimated annual consumption is around 21 600 µg. The most economically advantageous tender will be selected based on the lowest price, with quality considered as minimum requirements.

    About the bid

      The HUS Group requests tenders for Human Cot-1 DNA . Human Cot-1 DNA is a reagent used in the array process during hybridization. The procurement includes the following products: - Product group 1: Human Cot-1 DNA The procurement is not divided into lots. The estimated consumption of Human Cot-1 DNA per year would be around 21 600 µg. The product is described in more detail in below the invitation to tender and in Appendix 2 (Price and Product Form). The goal of this competitive procurement is to have good product delivery reliability and to have products available when they are needed. The most economically advantageous tender shall be selected. The criterion for determining the most economically advantageous tender shall be the lowest price. Quality is taken into account as minimum requirements. The procedure for carrying out the comparison, as well as the associated calculation formulas, are explained in more detail in Appendix 2 (Price and Product Form) and in the "General criteria of the group" section. The Agreement is in force for a fixed period of 2 years, and thereafter until terminated. The aim is to bring the agreement into force as soon as possible after the procurement procedure has been completed. The estimated starting day for the contract period is 30.4.2026. The products requested in this invitation to tender will be used by the Genetics Laboratory of the HUS Diagnostic Center (Helsinki University Hospital, HUS Group). See Appendix 1 (Agreement) of the call for tenders for details. The total estimated value of the procurement (VAT 0%) is approximately EUR 80 000 for 48 months. This is an estimate and the contracting entity does not commit neither to the stated euro amounts and nor the consumption figures indicated in the invitation to tender. The final order quantities may be higher or lower than stated. The subject matter and requirements of the procurement are described in detail in the invitation to tender and its annexes.Main features of the procedurePROCUREMENT PROCEDURE This procurement is so called "national procurement". It is estimated to be under the EU threshold value defined in the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). According to 100 § of Public Procurement Act the contracting entity shall outline the procurement procedure that it applies in the call for tenders documents. Procurement procedure is described as follows: PROCESSING OF TENDERS The procedure shall include the following phases: Contracting entity 1. Opens the tenders 2. Verifies the suitability of the tenderer 3. Checks that the tenders conform to the invitation to tender 4. Compares the tenders [POSSIBLE TRIAL USE] 5. Requests and checks certificates and reports on the suitability of the winning tenderer(s) 6. Makes a procurement decision and communicates it to all the tenderers 7. Concludes an agreement with the selected tenderer(s) In steps 2.-5. a contracting entity may (i) select as the winner of the competitive tendering the tenderer best evaluated on the basis of the comparative criteria; or (ii) move to a negotiated procedure. A negotiated procedure may be used if: (i) the competitive tendering procedure did not result in tenders that match the call for tenders; (ii) no tenders could be accepted due to a too high price or other reason; or (iii) HUS deems it necessary to negotiate the details of the tenders All tenderers who have submitted a tender within the time limit and meet the suitability requirements shall be invited to negotiate. The aim of the negotiations is to update the original call for tenders so that the tenderers selected for the negotiations can submit new tenders on the basis of it. Negotiations are conducted on an equal basis with all invited tenderers for the time specified by the HUS. After the negotiations, HUS will deliver an updated call for tenders to all bidders involved in the negotiations, on the basis of which the tenderers will submit new tenders. New tenders are compared according to the criteria described in the new call for tenders and the winning tenderer is selected on the basis of this comparison. Once the winner of the tendering process has been selected, HUS will make the procurement decision and communicate the decision to all tenderers. LANGUAGE OF THE COMPETITIVE TENDERING PROCEDURE The procurement documents are available in English. If a tenderer needs the documents in another language, the tenderer shall be responsible for translation and liable for the associated costs. Tenders must be prepared in English. PARTIAL TENDERS Partial tenders will not be accepted. PARALLEL TENDERS Parallel tenders are permitted. If a tenderer submits a parallel tender, the parallel tender must meet all the requirements of the invitation to tenders and have the required appendices. Parallel tenders must always be submitted as separate tenders. No more than one (1) parallel tender may be submitted.

      Contact name
      Procurement Services
      Contact phone
      +358 94711
      Contact email
      kilpailutus.tiimi@hus.fi
      Address
      Uutistie 5, 01770 Vantaa

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

    • Description

      Lowest price.

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    HUS-yhtymä
    Title
    Human Cot-1 DNA
    Type
    CompetitionPrequalification
    Main code
    33696500Laboratory reagents
    Supplemental codes

    No supplemental codes from buyer…

    Location
    Helsinki-Uusimaa
    Duration
    24 months

    Active similar competitions

    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      Competition7. okt. 2026
      9. nov. 2026(11 days)
    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      REQUEST FOR INFORMATION: SPRI Beads

      HUS-yhtymä is planning the procurement of DNA size selection reagents based on paramagnetic beads, utilizing SPRI technology for selective binding and purification of DNA fragments, to be used in next-generation sequencing (NGS) library preparation. Suppliers can provide feedback and input by submitting a response via email to kilpailutus.diagnostiikka@hus.fi, addressing all requirements, providing requested information and documentation, and identifying any concerns or proposed amendments to the draft agreement.

      Planning18. aug. 2026
      1. nov. 2026(3 days)
    • HUS-yhtymä

      Laboratorie-kits og reagenser

      Automaattinen nukleiinihappojen eristyslaite

      HUS-yhtymä suunnittelee automaattisen nukleiinihappojen eristyslaitteen hankintaa HUS Diagnostiikkakeskuksen Kliinisen mikrobiologian nukleiinihappoanalytiikkaan, sisältäen laitteen, varalaitteen tai kaksi erillistä eristysmoduulia sekä tarvittavat reagenssit ja tarvikkeet. Hankittavalla laitteella on tarkoitus eristää bakteeri-DNA:ta useista eri näytemateriaaleista, ja eristetyn tuotteen tulee olla validoitu bakteerien 16S-geenin PCR-monistamiseen Sanger-sekvensoinnilla. Toimittajia pyydetään tutustumaan liitteenä oleviin kysymyksiin ja toimittamaan vastaukset sähköpostitse osoitteeseen kilpailutus.diagnostiikka@hus.fi. bioMérieux Suomi OY:llä on todennäköisesti sopimus tällä hetkellä.

      Planning16. sep. 2026
      16. jan. 2027(79 days)
    • HUS-yhtymä

      Helse- og sosial tjenesteyting

      HUS Subcontracting genetic diagnostic tests

      HUS Group needs genetic diagnostic test services to support clinical patient work and individual patient treatment decisions. These services are for various clinics within the HUS Joint Municipal Authority for Specialised Health Care, and also for ISLAB (Eastern Finland Laboratory Centre, Joint Authority Enterprise). The services are procured through a dynamic purchasing system. Suppliers must have a yearly turnover of at least EUR 500,000, a risk category of RL1-RL3, professional experience with similar genetic diagnostic test services for reference customers during the last three years, and the laboratory must have accreditation status secured for at least two years. Additionally, candidates must have experience in supplying at least 5000 genetic studies yearly for university-level or similar hospitals within the EU/EEA area. Award criteria for specific competitions will be based on overall financial affordability, which may include price and/or quality.

      Dynamic purchasing system24. mars 2025
      9. mai 2030(100+ days)